Medical management of common urinary calculi

American Family Physician

Volumn 74, Issue 1, 2006, Pages 86-94

  Pietrow, Paul K ^a,b   Karellas, Michael E ^a  

^a UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^b Hudson Valley Urology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETOHYDROXAMIC ACID; ALLOPURINOL; ANTIBIOTIC AGENT; CITRATE POTASSIUM; CITRIC ACID; CYSTEINE; PENICILLAMINE; POTASSIUM CHLORIDE; STRUVITE; TAMSULOSIN; THIAZIDE DIURETIC AGENT; TIOPRONIN; UREASE INHIBITOR;

BLOOD ANALYSIS; CALCIUM INTAKE; CALCIUM OXALATE STONE; CYSTINURIA; DEEP VEIN THROMBOSIS; DIET; DIETARY INTAKE; FLUID INTAKE; FLUID THERAPY; FOOD INTAKE; GENETIC PREDISPOSITION; HUMAN; HYPERCALCEMIA; HYPERCALCIURIA; HYPEROXALURIA; HYPERURICEMIA; HYPERURICOSURIA; NEPHROLITHIASIS; RECURRENT DISEASE; REVIEW; RISK ASSESSMENT; RISK FACTOR; SODIUM RESTRICTION; URIC ACID STONE; URINALYSIS; UROLITHIASIS;

ACUTE DISEASE; ALGORITHMS; DIAGNOSIS, DIFFERENTIAL; DIET; FLANK PAIN; FLUID THERAPY; HUMANS; NEPHROSTOMY, PERCUTANEOUS; RISK FACTORS; STENTS; URINARY CALCULI;

EID: 33745896504     PISSN: 0002838X     EISSN: 0002838X     Source Type: Journal    
DOI: None     Document Type: Review

References (30)

1. Pearle MS, Calhoun EA, Curhan GC. Urologic diseases in America project: urolithiasis. J Urol 2005;173:848-57.
2. Delvecchio FC, Preminger GM. Medical management of stone disease. Curr Opin Urol 2003;13:229-33.
3. Menon M, Resnick MI. Urinary lithiasis: etiology, diagnosis, and medical management. In: Campbell MF, Walsh PC, Retik AB, eds. Campbell's Urology. 8th ed. Philadelphia, Pa.: Saunders, 2002.
4. Mandel N. Mechanism of stone formation. Semin Nephrol 1996;16:364-74.
5. Smith RC, Rosenfield AT, Choe KA, Essenmacher KR, Verga M, Glickman MG, et al. Acute flank pain: comparison of non-contrast-enhanced CT and intravenous urography. Radiology 1995;194:789-94.
6. Fielding JR, Steele G, Fox LA, Heller H, Loughlin KR. Spiral computerized tomography in the evaluation of acute flank pain: a replacement for excretory urography. J Urol 1997;157:2071-3.
7. Segura JW, Preminger GM, Assimos DG, Dretler SP, Kahn RI, Lingeman JE, et al. Ureteral Stones Clinical Guidelines Panel summary report on the management of ureteral calculi. J Urol 1997;158:1915-21.
8. Porpiglia F, Ghignone G, Fiori C, Fontana D, Scarpa RM. Nifedipine versus tamsulosin for the management of lower ureteral stones. J Urol 2004;172:568-71.
9. Chandhoke PS. When is medical prophylaxis cost-effective for recurrent calcium stones? J Urol 2002;168:937-40.
10. Lotan Y, Cadeddu JA, Roerhborn CG, Pak CY, Pearle MS. Cost-effectiveness of medical management strategies for nephrolithiasis. J Urol 2004;172(6 pt 1):2275-81.
11. Qiang W, Ke Z. Water for preventing urinary calculi. Cochrane Database Syst Rev 2004;(3):CD004292.
12. Borghi L, Meschi T, Amato F, Briganti A, Novarini A, Giannini A. Urinary volume, water and recurrences in idiopathic calcium nephrolithiasis: a 5-year randomized prospective study. J Urol 1996;155:839-43.
13. Borghi L, Schianchi T, Meschi T, Guerra A, Allegri F, Maggiore U, et al. Comparison of two diets for the prevention of recurrent stones in idiopathic hypercalciuria. N Engl J Med 2002;346:77-84.
14. Curhan GC, Willett WC, Rimm EB, Speizer FE, Stampfer MJ. Body size and risk of kidney stones. J Am Soc Nephrol 1998;9:1645-52.
15. Taylor EN, Stampfer MJ, Curhan GC. Obesity, weight gain, and the risk of kidney stones. JAMA 2005;293:455-62.
16. Tiselius HG. Recurrent stone formation in patients treated by ESWL. J Stone Dis 1992;4:152-7.
17. Holmes RP, Goodman HO, Assimos DG. Contribution of dietary oxalate to urinary oxalate excretion. Kidney Int 2001;59:270-6.
18. Pak CY, Fuller C, Sakhaee K, Preminger GM, Britton F. Long-term treatment of calcium nephrolithiasis with potassium citrate. J Urol 1985;134:11-9.
19. Allie-Hamdulay S, Rodgers AL. Prophylactic and therapeutic properties of a sodium citrate preparation in the management of calcium oxalate urolithiasis: randomized, placebo-controlled trial. Urol Res 2005;33:116-24.
20. Gault MH, Chafe LL, Morgan JM, Parfrey PS, Harnett JD, Walsh EA, et al. Comparison of patients with idiopathic calcium phosphate and calcium oxalate stones. Medicine (Baltimore)1991;70:345-59.
21. Coe FL, Parks JH, Nakagawa Y. Inhibitors and promoters of calcium oxalate crystallization. In: Coe FL, Favus MJ, eds. Disorders of Bone and Mineral Metabolism. New York, N.Y.: Raven Press, 1992.
22. Moe OW, Abate N, Sakhaee K. Pathophysiology of uric acid nephrolithiasis. Endrocrinol Metab Clin North Am 2002;31:895-914.
23. Kramer HJ, Choi HK, Atkinson K, Stampfer M, Curhan GC. The association between gout and nephrolithiasis in men: the health professionals' follow-up study. Kidney Int 2003;64:1022-6.
24. Shekarriz B, Stoller ML. Uric acid nephrolithiasis: current concepts and controversies. J Urol 2002;168(4 pt 1):1307-14.
25. Nemoy NJ, Staney TA. Surgical, bacteriological, and biochemical management of "infection stones." JAMA 1971;215:1470-6.
26. Rous SN, Turner WR. Retrospective study of 95 patients with staghorn calculus disease. J Urol 1977;118:902-4.
27. Koga S, Arakaki Y, Matsuoka M, Ohyama C. Staghorn calculi - long-term results of management. Br J Urol 1991;68:122-4.
28. Fishbein WN, Carbone PP. Urease catalysis: II. Inhibition of the enzyme by hydroxyurea, hydroxylamine, and acetohydroxamic acid. J Biol Chem 1965;240:2407-14.
29. Griffith DP, Khonsari F, Skurnick JH, James KE. A randomized trial of acetohydroxamic acid for the treatment and prevention of infection-induced urinary stones in spinal cord injury patients. J Urol 1988;140:318-24.
30. Pietrow PK, Auge BK, Weizer AZ, Delvecchio FC, Silverstein AD, Mathias B, et al. Durability of the medical management of cystinuria. J Urol 2003;169:68-70.